These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 17139760)
1. Generic drugs go to market. Effective, safe and less expensive. Mayo Clin Health Lett; 2006 Sep; 24(9):4-5. PubMed ID: 17139760 [No Abstract] [Full Text] [Related]
2. The generic drug approval process. Rheinstein PH Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762 [No Abstract] [Full Text] [Related]
3. Epo, by any other name. Nature; 2007 Sep; 449(7160):259. PubMed ID: 17882170 [No Abstract] [Full Text] [Related]
4. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law. Dinh TQ Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027 [No Abstract] [Full Text] [Related]
5. SuperGenerics: a better alternative for biogenerics. Charles SA Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591 [No Abstract] [Full Text] [Related]
6. A comparison of United States and Canadian laws as they affect generic pharmaceutical market entry. Hore E Food Drug Law J; 2000; 55(3):373-88. PubMed ID: 11824466 [No Abstract] [Full Text] [Related]
7. Generic drug companies are the winners. Voth AJ CMAJ; 1991 Nov; 145(9):1081. PubMed ID: 1751924 [No Abstract] [Full Text] [Related]
8. Branded drug reformulation: the next brand vs. generic antitrust battleground. Amoresano GV Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032 [No Abstract] [Full Text] [Related]
9. [Why patent-protected drugs' cost efficiency should be compared with generic preparations]. Berggren F; Lundin D; Ramsberg J Lakartidningen; 2006 Jan 25-31; 103(4):223-4. PubMed ID: 16491555 [No Abstract] [Full Text] [Related]
13. Brands in peril as Brazil strives to keep AIDS drugs free. Butler D Nature; 2004 Jun; 429(6991):493. PubMed ID: 15175719 [No Abstract] [Full Text] [Related]
14. FDA's role in administering the Hatch-Waxman Act. Malkin BJ Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575 [No Abstract] [Full Text] [Related]
15. Statin utilisation--recognising the role of the invisible hand. Minhas R Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171 [No Abstract] [Full Text] [Related]
16. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises. Gorlin DI Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385 [No Abstract] [Full Text] [Related]
17. The GO License: only part of the solution. Batson A; Milstien JB Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489 [TBL] [Abstract][Full Text] [Related]
18. Reinventing an industry. Mandavilli A Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817 [No Abstract] [Full Text] [Related]
19. [What drug companies actually do]. Tonby K Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1806. PubMed ID: 17599137 [No Abstract] [Full Text] [Related]